Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis

NCT05866809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG: HK-660S
DRUG: Placebo

Sponsor

CuromeBiosciences